|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Differences in the Wnt microenvironment in AC and SCC of NSCLC lead to PPARgamma decrease via mechanisms that differentially alter endothelial cell motility and branching which in turn can influence therapeutic response.
|
27876017 |
2016 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
By contrast, the antigen presenting canonical pathway (P=0.038) appeared to be linked to PPARγ in AC.
|
23707988 |
2013 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This is the first PPARG germline mutation associated with dyslipidemia and colonic polyp formation that can progress to full-blown adenocarcinoma.
|
20123124 |
2010 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease.
|
18372284 |
2008 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In an effort to evaluate the importance of this variant, we determined the expression level of PPARgamma and that of the splicing variant ORF4 in a series of 28 human colon adenocarcinomas relative to paired normal mucosa by real-time PCR.
|
17611675 |
2007 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
PPARgamma, COX-2 and p-IkB-alpha expression did not correlate with the stage or differentiation of the adenocarcinomas.
|
16215757 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of PPAR(gamma) in H2122 adenocarcinoma cells (H2122-PPAR(gamma)) blocked anchorage-independent growth compared to cells transfected with empty vector (H2122-LNCX), but had no significant effect on cell proliferation or apoptosis under standard tissue culture conditions.
|
15608671 |
2005 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, PPARgamma(+/-) mice had an almost 3-fold increase in mammary adenocarcinomas (P < 0.05), an over 3-fold increase in ovarian granulosa cell carcinomas (P < 0.05), an over 3-fold increase in malignant tumors (P < 0.02) and a 4.6-fold increase in metastatic incidence.
|
15073042 |
2004 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Simultaneous treatment with a PPARgamma ligand and PB enhanced the growth inhibition in adenocarcinomas but not in nonadenocarcinomas.
|
11948134 |
2002 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of PPAR-gamma protein was higher in an adenocarcinoma cell line (TE-7 cells) than in a squamous cell carcinoma cell line (TE-1 cells).
|
11494023 |
2001 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry was used to demonstrate the presence of PPARgamma protein in surgically resected specimens from well differentiated, moderately differentiated and poorly differentiated adenocarcinoma.
|
11044367 |
2000 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Immunohistochemical study of resected human pancreata using a polyclonal PPARgamma antibody revealed that PPARgamma protein expression in the nuclei of carcinoma cells was observed in 9 of 10 pancreatic adenocarcinomas.
|
11034103 |
2000 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In the present study, we show that PPARgamma is expressed in human prostate adenocarcinomas and cell lines derived from these tumors.
|
10984506 |
2000 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical study of resected human pancreata using a polyclonal PPARgamma antibody revealed that PPARgamma protein expression in the nuclei of carcinoma cells was observed in 9 of 10 pancreatic adenocarcinomas.
|
11034103 |
2000 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We show here that PPARgamma is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines.
|
9734398 |
1998 |